In vitro selective concentrations of cefepime and ceftazidime for AmpC β-lactamase hyperproducer Enterobacter cloacae variants

Clinical Microbiology and Infection

Volumn 5, Issue SUPPL. 1, 1999, Pages

  Negri, María Cristina ^a   Baquero, Fernando ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

AmpC lactamase; Cefepime; Enterobacter

Indexed keywords

BETA LACTAMASE; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE;

CONFERENCE PAPER; ENTEROBACTER CLOACAE; NONHUMAN; PRIORITY JOURNAL;

ENTEROBACTER; ENTEROBACTER CLOACAE;

EID: 0033031579     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.1999.tb00721.x     Document Type: Conference Paper

References (7)

1. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115: 585-90.
2. Sanders CC, Sanders E Jr. Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamases and implications for the future. Rev Infect Dis 1983; 5: 639-48.
3. Jacobs C, Huang LJ, Bartowsky E, Normark S, Park JT. Bacterial cell wall recycling provides cytosolic muropeptides as effectors for beta-lactamase inductiòn. EMBO J 1994; 13: 4684-94.
4. Sanders EW Jr, Tenney JH. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin Infect Dis 1996; 23: 454-61.
5. Negri MC, Morosini MI, Loza E, Baquero F. In-vitro selective antibiotics concentrations of beta-lactams for penicillin resistant Streptococcus pneumoniae populations. Antimicrob Agents Chemother 1994; 38: 122-5.
6. Baquero F, Negri MC. Selective compartments for resistant microorganisms in antibiotic gradients. BioEssays 1997: 731-6.
7. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. M7-A3. Villanova, PA: NCCLS, 1995.